← All trials
NCT05203601
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 26, 2020
- Primary completion
- Oct 26, 2022
- Completion date
- Oct 26, 2023
- First posted
- Jan 24, 2022
- Last posted
- Feb 7, 2022
- Enrollment
- 68
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- Fudan UniversityCollaborator
- Fudan UniversityOverall official - principal investigator
- China National Biotec Group Co., LtdStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.